The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant ...
ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer ...
The Food and Drug Administration approved Zytiga (abiraterone) to treat metastatic hormone-resistant prostate cancer on April 28, 2011. The approval is for patients who have received prior Taxotere ...
HORSHAM, Pa., March 30, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a label update for ZYTIGA® (abiraterone acetate) plus prednisone based on the final analysis of ...
Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer RARITAN, N.J., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback